Asad Rauf

Engineer, Physican, & Tech Enthusiast. @UtahCOE 🔧 @ILLINOISmed 🩺 @CCF_IMCHIEFS👨🏾‍⚕️Future Oncologist @SylvesterCancer
Other Stuff: @AsadRaufSLC

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

A recent @HuffPost article featuring our very own Dr. Thomas Platè (@DrPlatelet) explores how to recognize iron deficiency, when supplementation may be appropriate and why taking too much iron can carry serious health risks.

As Dr. Platè explains, iron needs vary based on factors like age, pregnancy status and the underlying cause and severity of a deficiency. Taking excessive amounts over time can lead to iron buildup in organs such as the heart and liver, potentially causing serious complications. https://t.co/YMNiHXEMpK

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

Sylvester Comprehensive Cancer Center has been named the #1 cancer program in Florida and #23 in the nation in the 2026-2027 U.S. News & World Report Best Hospitals rankings!

This recognition reflects the expertise and dedication of the physicians, nurses, researchers, trainees, and staff who work every day to deliver exceptional cancer care.

Most importantly, thank you to our patients and families for trusting us with your care. We're honored to be part of your journey and remain committed to advancing cancer research and care. Learn more from Dr. Stephen Nimer (@DrSDNimer), our cancer center director, about why this recognition matters: https://t.co/Av8cjFTNAv.

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

🚨 The @US_FDA has approved datopotamab deruxtecan (Dato-DXd) for patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy.

The approval was based on results from the international Tropion-Breast02 clinical trial, led in the U.S. by MSK breast medical oncologist Dr. Tiffany Traina. Learn more: https://t.co/LWY0SMzD9n

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

New research led by Dr. Gerald Soff was presented at @ASCO, which suggests the oral medication avatrombopag may help patients with gastrointestinal cancers avoid chemotherapy delays caused by low platelet counts. 🙌

In a phase 2 clinical trial, avatrombopag demonstrated strong effectiveness in treating chemotherapy-induced thrombocytopenia (CIT). Learn more: https://t.co/nhKTGzFtbJ. #GIcancer #Hematology

[William Gibson @wgibson]

RevMed just doubled overall survival in pancreatic cancer by using CypA-targeting molecular glues to potently drug oncogenic KRAS-ON, long deemed untouchable.

One funny thing is that probably the most fundamental insight for daraxonrasib sits in a PNAS paper that's been cited merely 84 times. This showed that molecular glues can coax an endogenous protein to wrap itself around utterly featureless surface. The other is a 2017 Cell Reports paper (just 68 citations) on how Sanglifehrin A can be used to repurpose CypA's surface. A lot of the game-changing stuff seems niche and unglamorous at first.

Greg Verdine is having a chembio Annus Mirabilis for his 2025-2026 streak: FOG-001, Daraxonrasib. He provided much of the foundational conceptual work behind taking out both Beta-catenin and KRAS*.

*of course many others contributed immensely, but let's give some credit where credit is due!

[Nicholas Hornstein @GIMedOnc]

RevMed with huge news for pancreatic cancer (daraxonrasib).

The headline is hard to ignore 👀

• Median OS 13.2 vs 6.7 months
• HR ~0.4 📉
• Activity across KRAS variants (not just G12C)
• Manageable safety

If that signal is real, this isn’t incremental. It changes how we think about KRAS.

But—caveat applies ⚠️
This is a press release! PR as a rule is rosier than real data.

Still… an OS HR like that gets your attention.

Feels like we may be moving from mutation-specific inhibition → broader KRAS control.

That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see.

Now we wait for the data behind the headline.

@TheGutOncLab @OncoAlert @Onco_Nexus

https://t.co/MBsxalyQT3

[Charles Swanton @CharlesSwanton]

People often ask how breakthroughs occur in cancer biology-often the story is more complex - the survival plot for myeloma outcomes is extraordinary - improvements come about in incremental steps - in my lifetime treatment of Myeloma has almost transformed into a curable disease

[Wassim Laroussi @WassimLaroussi3]

Claude now with a https://t.co/BScgZfW1H5 integration. So cool!

[Denis Wirtz @deniswirtz]

Federal funding for US biomedical research is moribund.

Since October 1 2025, NIH is -80% in new grants and -70% in values (total dollars).

Labs are closing down and researchers are leaving science.

To what end?

[CCF Cardiology Fellows @CCFcards]

Pradeep is a machine, with an absolutely impressive procedural log:

🦢 Swan-Ganz Catheters: 18
🫁 Thoracentesis: 17
⚡️ Active Fixation TVPs: 7
❤️ Pericardiocentesis: 6
🎈 IABP: 2
💉 Large Bore Access: 10
🪡 Arterial Lines: 15

And many TTEs, DCCVs in a state of the art CICU!

[Miami Hem/Onc Program Director @HemOncMiami]

In an interview surrounding new data from the 2026 ASCO Gastrointestinal Cancers Symposium, @d_tuerff - our second year fellow @SylvesterCancer discussed with @GIMedOnc
about the evolving role of the BREAKWATER trial in BRAF V600E–mutated metastatic colorectal cancer.
@OncBrothers @OncUpdates @PeterHoseinMD @GlopesMd

[Asad Rauf @AsadARauf]

@GlopesMd @univmiami @SylvesterCancer 🙌🏽🙌🏽🙌🏽🙌🏽🌀🌀🌀 what a game!

[ABC News @ABC]

The U.S. has surpassed 2,000 measles cases for the first time in more than 30 years, according to data from the CDC. https://t.co/KTiPxK226v

[Brad Stulberg @BStulberg]

A massive new study on peak performance included 34,000 international top performers: Nobel laureates, renowned classical music composers, Olympic champs, and the world’s best chess players. It shows early specialization is a trap, and the road to greatness is long and varied.

[Miami Hem/Onc Program Director @HemOncMiami]

Proud of our first-year fellow, @Valardilaavila for delivering an oral presentation at #ASH25 as part of her Hematology Inclusion Pathway Award!
This award supports minority researchers with funding, mentorship, and the opportunity to present at the ASH Annual Meeting.
A huge achievement! @SylvesterCancer @Drjhoffmanmiami

[Asad Rauf @AsadARauf]

@johnhanna0 @MDAndersonNews Congrats John!

[Asad Rauf @AsadARauf]

@CalcagnoTess @UofUCV @CCF_IMCHIEFS Congrats! Enjoy my hometown! ❤️⛰️🏞️🧗🏽‍���️🗻🌲

[Asad Rauf @AsadARauf]

Despite the historical challenges in treating SCLC, this novel ADC is reigniting hope with durable responses. Read our analysis! ⬇️ @Jani_Chinmay @AmanChauhanMD @SylvesterCancer @HemOncMiami
https://t.co/6wFzAYQAb9

[Miami Hem/Onc Program Director @HemOncMiami]

📸 Our yearly professional photoshoot - a perfect mix of elegance and fun!
From sharp white-coats to candid laughs, it’s always a reminder of how far we’ve come and the amazing people we work with. 😄💼✨@SylvesterCancer @Drjhoffmanmiami @Jani_Chinmay @Alsbihi93 @palashasawa @AksheeBatra @samanthawarrak @MichaelDurante1 @d_tuerff @assalazar87 @AsadARauf

[Scott Cameron 🏴󠁧󠁢󠁳󠁣󠁴󠁿🇺🇸🫀🩺📟🔬🧫🧬🥋 @2Scottish]

🚨Our ABIM Research Pathway in IM is live on ERAS!🔬Triple Match:✅ Internal Medicine (2 yrs)✅ Subspecialty Fellowship✅ Research (3 yrs). Join a world-class clinical team w/ mentored science. ERAS Code:1968140C5 Pls share ! #MedTwitter #IMMatch #MEdEd @IMresident @CCF_IMCHIEFS